In Vijayawada city of Andhra Pradesh, Lupin has opened a new satellite laboratory. The move is a part of Lupin Diagnostics’ ongoing growth strategy, which aims to improve access to high-quality testing services and broaden the diagnostics network throughout the nation. With total 27 laboratories and more than 410 collection centres spread across India, Lupin Diagnostics’ broad network is now complete with the newly opened laboratory. This growth demonstrates Lupin’s dedication to provide complete diagnostic solutions and solidifying its leadership in the diagnostics sector.
Modern diagnostic technology is available in Lupin’s new Vijayawada laboratory, which is staffed by a group of highly skilled clinical professionals. Lupin Diagnostics is able to provide the neighbourhood with trustworthy and superior diagnostic services thanks to this cutting-edge infrastructure. Cutting-edge technology and expertise are combined to ensure accurate and effective testing, prompt diagnosis, and improved patient care.
Today, the Lupin stock opened at Rs 777.75, with a high and low of Rs 785.00 and Rs 776.20. Shares today closed at Rs 778.85, up by 0.16% from its previous close of Rs 777.60. The stock has a 52-week high of Rs 799.65 and a 52-week low of Rs 583.05. The current market cap of Lupin Ltd is Rs 35,439.69.
Lupin is regarded as one of the biggest producers of anti-tuberculosis medications in the world. The business holds a sizeable market share in a number of therapeutic categories, including cardiovascular (statins and prils), diabetes, asthma, pediatrics, gastrointestinal (GI), anti-infective (AI) and non-steroidal anti-inflammatory drugs (NSAIDs). Additionally, the business has been proud to hold onto its global leadership positions in other therapy areas including anti-TB and cephalosporin over the years.